CD164: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

CD164: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

Introduction

CD164, also known as Multi-Glycosylated Core Protein 24 (MGC24), is a cytoskeleton-associated protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure, which consists of a glycosylated core and N- and C-terminal cytoplasmic domains, makes it an attractive target for small molecule inhibitors. In this article, we will discuss the biology of CD164, its potential drug targets, and its potential as a biomarker for various diseases.

CD164 biological background

CD164 is a protein expressed in a variety of cells and is mainly distributed in the cytoplasm. It plays an important role in cell division, cell growth and cytoskeletal assembly. CD164 is a transmembrane protein that is evenly distributed inside the cell membrane but highly aggregated in the cytoplasm. It plays a key role in a variety of physiological processes, such as cell division, cell growth, apoptosis, and cell morphology maintenance.

The role of CD164 in disease

1. Cancer

CD164 is expressed in a variety of cancers, such as lung cancer, liver cancer, breast cancer, etc. Studies have shown that the expression level of CD164 is positively correlated with the aggressiveness and metastasis of cancer. In addition, inhibition of CD164 can significantly inhibit the growth and metastasis of cancer cells. Therefore, CD164 is considered a potential cancer therapeutic target.

2. Neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, etc., are closely related to the abnormal expression of CD164. Studies have found that overexpression of CD164 is an important cause of the occurrence and development of neurodegenerative diseases. In addition, inhibition of CD164 can significantly improve symptoms of neurodegenerative diseases, such as cognitive function, motor function, and depression.

3. Immune diseases

Immune diseases, such as autoimmune diseases, inflammatory bowel disease, etc., are also closely related to abnormal expression of CD164. Studies have shown that overexpression of CD164 is an important cause of immune cell dysfunction, exacerbation of inflammatory responses, and the occurrence of autoimmune diseases. In addition, inhibition of CD164 can significantly improve the function of the immune system and reduce the degree of inflammation in the immune response.

Pharmacological significance of CD164

1. Selective CD164 inhibitors

CD164 is a potential drug target because its unique structure makes designing specific CD164 inhibitors a challenging task. At present, there are already drugs developed by some companies, such as Aurora, C Wheelchair and PTC-4289, which treat various diseases by inhibiting the activity of CD164. These drugs have shown good efficacy in animal experiments and have entered the clinical research stage.

2. CD164-based tumor immunotherapy

Tumor immunotherapy is a new treatment method that uses the immune system to attack tumors. CD164 is an important target in tumor immunotherapy. Studies have shown that inhibition of CD164 can significantly enhance the efficacy of tumor immunotherapy, such as improving tumor immunogenicity, enhancing tumor T cell infiltration, and improving tumor survival rate.

3. CD164 disease diagnosis

CD164 is expressed in a variety of diseases and therefore can be used as a potential disease diagnostic indicator. For example, in neurodegenerative diseases, overexpression of CD164 is used as a biomarker for disease diagnosis. In addition, inhibition of CD164 is also used as a biomarker for the treatment of diseases, such as cancer, neurodegenerative diseases, and immune diseases.

Conclusion

CD164 is a protein expressed in a variety of cells and plays an important role in cell division, cell growth and cytoskeletal assembly. In cancer, neurodegenerative diseases and immune diseases, abnormal expression of CD164 is closely related to the aggressiveness, metastasis and symptoms of the disease. Therefore, CD164 is considered a potential drug target. In addition, inhibition of CD164 can significantly improve the symptoms of various diseases, such as cancer, neurodegenerative diseases, and immune diseases. Therefore, CD164 serves as a potential drug target and highly

Protein Name: CD164 Molecule

Functions: Sialomucin that may play a key role in hematopoiesis by facilitating the adhesion of CD34(+) cells to the stroma and by negatively regulating CD34(+)CD38(lo/-) cell proliferation. Modulates the migration of umbilical cord blood CD133+ cells and this is mediated through the CXCL12/CXCR4 axis. May play an important role in prostate cancer metastasis and the infiltration of bone marrow by cancer cells. Promotes myogenesis by enhancing CXCR4-dependent cell motility. Positively regulates myoblast migration and promotes myoblast fusion into myotubes (By similarity)

More Common Targets

CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20